Parallax Volatility Advisers’s Nektar Therapeutics NKTR Stock Holding History

Parallax Volatility Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-900	Closed	-$51K	–	3269
2022 Q2	$51K	Sell	900 -507	-36%	-$32K	﹤0.01%	2465
2022 Q1	$114K	Buy	+1,407	New	+$208K	﹤0.01%	2328
2021 Q4	–	Sell	-1,373	Closed	-$370K	–	2178
2021 Q3	$370K	Sell	1,373 -700	-34%	-$168K	﹤0.01%	1577
2021 Q2	$534K	Buy	+2,073	New	+$574K	﹤0.01%	1141
2019 Q1	–	Sell	-40	Closed	-$20K	–	3596
2018 Q4	$20K	Sell	40 -7,460	-99%	-$4.5M	﹤0.01%	2404
2018 Q3	$6.86M	Sell	7,500 -12,467	-62%	-$10.6M	0.01%	595
2018 Q2	$14.6M	Buy	+19,967	New	+$23M	0.02%	341
2018 Q1	–	Sell	-3,000	Closed	-$2.69M	–	3571
2017 Q4	$2.69M	Buy	+3,000	New	+$1.77M	﹤0.01%	818

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Parallax Volatility Advisers's NKTR Position: Q4 2021 in Review

Parallax Volatility Advisers sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 306 shares — an estimated $82K sold.

Parallax Volatility Advisers first reported a position in NKTR in Q4 2017 and held it in 7 quarters. The position peaked at $16.3M in Q3 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

Parallax Volatility Advisers reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
Parallax Volatility Advisers sold 306 Nektar Therapeutics shares in Q4 2021, an estimated $82K.
Parallax Volatility Advisers first reported a position in Nektar Therapeutics in Q4 2017 and held it in 7 quarters.
Parallax Volatility Advisers's Nektar Therapeutics position peaked at $16.3M in Q3 2018.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Parallax Volatility Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.